Literature DB >> 17284699

Association of genetic variations with nonfatal venous thrombosis in postmenopausal women.

Nicholas L Smith1, Lucia A Hindorff, Susan R Heckbert, Rozenn N Lemaitre, Kristin D Marciante, Kenneth Rice, Thomas Lumley, Joshua C Bis, Kerri L Wiggins, Frits R Rosendaal, Bruce M Psaty.   

Abstract

CONTEXT: Although the roles of clotting proteins and enzymes that activate or inhibit fibrin production and lysis are well characterized, the underlying contribution of genetic variation in these constituents to risk of venous thrombosis (VT) has not been fully investigated.
OBJECTIVE: To describe the association of common genetic variation in 24 coagulation, anticoagulation, fibrinolysis, and antifibrinolysis candidate genes with risk of incident nonfatal VT in postmenopausal women. DESIGN, SETTING, AND PARTICIPANTS: Population-based case-control study conducted in a large integrated health care system in Washington State. Participants were perimenopausal and postmenopausal women aged 30 to 89 years who sustained a first VT event between January 1995 and December 2002 (n = 349) and 1680 controls matched on age, hypertension status, and calendar year (n = 1680). MAIN OUTCOME MEASURE: Risk of venous thrombosis associated with global variation within a gene as measured by common haplotypes and with individual haplotypes and single nucleotide polymorphisms (SNPs). Significance of the associations was assessed by a .20 threshold of the false-discovery rate q value, which accounts for multiple testing.
RESULTS: Only the tissue factor pathway inhibitor gene demonstrated global association with risk (q = .13). Five significant SNP associations were identified across 3 of the candidate genes (factors V, XI, and protein C) in SNP analyses. Two associations have been previously reported. Another 22 variants across 15 genes had P values less than .05 but q values between .20 and .35. Five of these confirm previously reported associations (fibrinogen genes and protein C), 2 were inconsistent with earlier reports (thrombomodulin and plasminogen activator inhibitor 1), and 15 were new discoveries.
CONCLUSIONS: After accounting for multiple testing, 5 SNPs associated with VT risk were identified, 3 of which have not been previously reported. Replication of these novel associations in other populations is necessary to corroborate these findings and identify which genetic factors may influence VT risk in postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17284699     DOI: 10.1001/jama.297.5.489

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  63 in total

1.  Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention.

Authors:  Elizabeth L Barry; Leila A Mott; Robert S Sandler; Dennis J Ahnen; John A Baron
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-19

2.  Genetic associations for activated partial thromboplastin time and prothrombin time, their gene expression profiles, and risk of coronary artery disease.

Authors:  Weihong Tang; Christine Schwienbacher; Lorna M Lopez; Yoav Ben-Shlomo; Tiphaine Oudot-Mellakh; Andrew D Johnson; Nilesh J Samani; Saonli Basu; Martin Gögele; Gail Davies; Gordon D O Lowe; David-Alexandre Tregouet; Adrian Tan; James S Pankow; Albert Tenesa; Daniel Levy; Claudia B Volpato; Ann Rumley; Alan J Gow; Cosetta Minelli; John W G Yarnell; David J Porteous; John M Starr; John Gallacher; Eric Boerwinkle; Peter M Visscher; Peter P Pramstaller; Mary Cushman; Valur Emilsson; Andrew S Plump; Nena Matijevic; Pierre-Emmanuel Morange; Ian J Deary; Andrew A Hicks; Aaron R Folsom
Journal:  Am J Hum Genet       Date:  2012-06-14       Impact factor: 11.025

3.  Genome-wide association study identifies novel loci for plasma levels of protein C: the ARIC study.

Authors:  Weihong Tang; Saonli Basu; Xiaoxiao Kong; James S Pankow; Nena Aleksic; Adrian Tan; Mary Cushman; Eric Boerwinkle; Aaron R Folsom
Journal:  Blood       Date:  2010-08-27       Impact factor: 22.113

4.  Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis.

Authors:  Nicholas L Smith; Kenneth M Rice; Edwin G Bovill; Mary Cushman; Joshua C Bis; Barbara McKnight; Thomas Lumley; Nicole L Glazer; Astrid van Hylckama Vlieg; Weihong Tang; Abbas Dehghan; David P Strachan; Christopher J O'Donnell; Jerome I Rotter; Susan R Heckbert; Bruce M Psaty; Frits R Rosendaal
Journal:  Blood       Date:  2010-12-16       Impact factor: 22.113

5.  Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  C R Lee; K E North; M S Bray; D J Couper; G Heiss; D C Zeldin
Journal:  Clin Pharmacol Ther       Date:  2007-05-09       Impact factor: 6.875

6.  F9 Malmö, factor IX and deep vein thrombosis.

Authors:  Irene D Bezemer; Andre R Arellano; Carmen H Tong; Charles M Rowland; Helen A Ireland; Kenneth A Bauer; Joseph Catanese; Pieter H Reitsma; Carine J M Doggen; James J Devlin; Frits R Rosendaal; Lance A Bare
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

7.  Prospective study of γ' fibrinogen and incident venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE).

Authors:  Aaron R Folsom; Weihong Tang; Kristen M George; Susan R Heckbert; Richard F MacLehose; Mary Cushman; James S Pankow
Journal:  Thromb Res       Date:  2016-01-12       Impact factor: 3.944

8.  A genome-wide association study for venous thromboembolism: the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium.

Authors:  Weihong Tang; Martina Teichert; Daniel I Chasman; John A Heit; Pierre-Emmanuel Morange; Guo Li; Bruno H Ch Stricker; Paul M Ridker; Aaron R Folsom; Nicholas L Smith; Nathan Pankratz; Frank W Leebeek; Guillaume Paré; Mariza de Andrade; Christophe Tzourio; Bruce M Psaty; Saonli Basu; Rikje Ruiter; Lynda Rose; Sebastian M Armasu; Thomas Lumley; Susan R Heckbert; André G Uitterlinden; Mark Lathrop; Kenneth M Rice; Mary Cushman; Albert Hofman; Jean-Charles Lambert; Nicole L Glazer; James S Pankow; Jacqueline C Witteman; Philippe Amouyel; Joshua C Bis; Edwin G Bovill; Xiaoxiao Kong; Russell P Tracy; Eric Boerwinkle; Jerome I Rotter; David-Alexandre Trégouët; Daan W Loth
Journal:  Genet Epidemiol       Date:  2013-05-05       Impact factor: 2.135

9.  Matrix metalloproteinase-3 (MMP3) and MMP9 genes and risk of myocardial infarction, ischemic stroke, and hemorrhagic stroke.

Authors:  Robert C Kaplan; Nicholas L Smith; Stanley Zucker; Susan R Heckbert; Kenneth Rice; Bruce M Psaty
Journal:  Atherosclerosis       Date:  2008-03-14       Impact factor: 5.162

10.  Genetic association studies and the effect of misclassification and selection bias in putative confounders.

Authors:  Christy L Avery; Keri L Monda; Kari E North
Journal:  BMC Proc       Date:  2009-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.